Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NA-901
- Development stage
- Unknown
- Lead developer
- Biomed
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
NA-901 is a first-in-class small molecule drug candidate developed by Biomed Industries and its subsidiary NeuroActiva for the treatment of Major Depressive Disorder (MDD). The drug is based on the company's proprietary neurogenesis platform, which focuses on stimulating the growth of new neurons and providing neuroprotection in the brain. NA-901 is designed to be blood-brain barrier (BBB) penetrant and has demonstrated a favorable safety profile in Phase 1B clinical trials, with no adverse side effects reported. It is currently in Phase 2B/3 development, representing a novel therapeutic approach to depression that targets structural plasticity and neuronal health rather than solely modulating monoamine neurotransmitters.
Beyond the preview
Go deeper on NA-901.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NA-901.